<p>Clinical Value Of Apatinib As A Salvage Treatment In Patients With Chemo-Refractory Advanced Cervical Cancer</p>

Abstract

Patients had to have failed at least 2 lines of chemotherapy prior to receiving apatinib. The clinical tumor response was evaluated after 4 weeks of apatinib treatment, and then every 8 weeks (two cycles). Progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), and adverse events were evaluated. Results: Twenty-five patients were included in this study. The median PFS was 5.8 months (95% CI, 4.65-6.95), and the median OS was 12.2 months (95% CI, 8.99-15.41). ORR was 48% and DCR was 96%. Complete response was not observed. The most common adverse events in this study (all grades) were hand-foot syndrome (48%), hypertension (20%), and mouth mucositis (20%). Conclusion: Apatinib monotherapy showed good therapeutic value with tolerable adverse events for patients with chemo-refractory advanced cervical cancer.

Effectiveness and prognostic factors of apatinib treatment in patients with recurrent or advanced cervical carcinoma: A retrospective study

“…Some recent research results show that apatinib has a certain effect on cervical cancer. In 2019, several studies reported the effect of single‐agent apatinib treatment after failure of first‐line treatment in recurrent or advanced cervical cancer 17,19–21 . In 2020, Guo et al 22 assessed the clinical efficacy and safety of apatinib combined with chemotherapy or concurrent chemo‐brachytherapy as first‐line treatment.…”

“…In 2019, several studies reported the effect of single‐agent apatinib treatment after failure of first‐line treatment in recurrent or advanced cervical cancer. 17 , 19 , 20 , 21 In 2020, Guo et al 22 assessed the clinical efficacy and safety of apatinib combined with chemotherapy or concurrent chemo‐brachytherapy as first‐line treatment. In comparison to the results from these studies, ORR, DCR and median PFS, and OS of our study seems a slightly higher than those reported in 2019, but lower than the finding from Guo et al in 2020.…”

“…Based on these biologic rationales, apatinib might affect the treatment of patients with cervical cancer. In the past year, some articles have reported that apatinib may be active in patients with recurrent and metastatic cervical cancer after failure of first‐line treatment 16–21 . However, fewer studies focus on finding which group of patients should be more beneficial from the treatment of apatinib.…”

“…In the past year, some articles have reported that apatinib may be active in patients with recurrent and metastatic cervical cancer after failure of first‐line treatment. 16 , 17 , 18 , 19 , 20 , 21 However, fewer studies focus on finding which group of patients should be more beneficial from the treatment of apatinib. Herein, the aim of this retrospective study was not only on the efficacy and safety of apatinib in patients with recurrent or advanced cervical cancer but also analysis the various prognostic factors in the different subgroups to find the most beneficial patients.…”

Clinical Efficacy and Safety of Apatinib for the Treatment of Patients with Metastatic, Recurrent Cervical Cancer after Failure of Radiotherapy and First-Line Chemotherapy: A Prospective Study

“…In clinical trials of advanced or recurrent cervical cancer, the median PFS with pazopanib, lapatinib and sunitinib was 18.1 weeks, 17.1 weeks and 3.5 months, respectively, and the ORR with pazopanib, lapatinib and sunitinib was 9.5, 5.1 and 0%, respectively [14,15]. A comparison between apatinib and other antiangiogenic drugs is shown in Table 5 [2,8,[14][15][16][17].…”